



ORIGINAL ARTICLE

The center effect in liver transplantation in the Eurotransplant region: a retrospective database analysis

Joris J. Blok¹ , Jacob D. de Boer^{1,2}, Hein Putter³, Xavier Rogiers⁴, Markus O. Guba⁵, Christian P. Strassburg⁶, Undine Samuel², Bart van Hoek⁷ , Jaap F. Hamming¹, Andries E. Braat¹ & the Eurotransplant Liver Intestine Advisory Committee

1 Division of Transplantation, Department of Surgery, Leiden University Medical Center, Leiden University, Leiden, The Netherlands

2 Eurotransplant International Foundation, Leiden, The Netherlands

3 Department of Medical Statistics, Leiden University Medical Center, Leiden University, Leiden, The Netherlands

4 Department of Surgery, Ghent University Hospital Medical School, Ghent, Belgium

5 Department of General, Visceral and Transplant Surgery, Hospital of the University of Munich, Munich, Germany

6 Department of Internal Medicine, University of Bonn, Bonn, Germany

7 Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden University, Leiden, The Netherlands

Correspondence

Joris J. Blok MD, Division of Transplantation, Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Tel.: +31-71-5266188;
fax: +31-71-5266952;
e-mail: j.j.blok@lumc.nl

SUMMARY

Apart from donor and recipient risk factors, the effect of center-related factors has significant impact on graft survival after liver transplantation (LT). To investigate this effect in Eurotransplant, a retrospective database analysis was performed, including all LT's in adult recipients (≥ 18 years) in the Eurotransplant region from 1.1.2007 until 31.12.2013. Additionally, a survey was sent out to all transplant centers requesting information on surgeons' experience and exposure. In total, 10 265 LT's were included (median follow-up 3.3 years), performed in 39 transplant centers. Funnel plots showed significant differences in graft survival between the transplant centers. After correction for donor and recipient risk, with the Eurotransplant donor risk index (ET-DRI) and the simplified recipient risk index (sRRI) and random effects, these differences diminished. Mean historical volume (in the preceding 5 years) was a significant ($P < 0.001$), nonlinear marker for graft survival in the multivariate analysis. This study demonstrates that funnel plots can be used for benchmarking purposes in LT. Case-mix correction can be performed with the use of the ET-DRI and sRRI. The center effect encompasses the entire complex process of preoperative workup, operation to follow-up.

Transplant International 2018; 31: 610–619

Key words

donor risk, Europe, outcome, risk factor

Received: 29 November 2017; Revision requested: 10 January 2018; Accepted: 30 January 2018; Published online 5 March 2018

Introduction

Apart from known donor risk and recipient risk factors [1–6], several studies have found that liver transplantation (LT) center factors represent significant predictors

of graft failure, independent of region, donor service area, or donor and recipient factors [7]. The hypothesis of center volume being the main 'center-related' risk factor for post-LT survival was confirmed by several studies from Europe [8] and the USA [9,10]; however,

these studies did not correct for donor and/or recipient risk. Northup *et al.* [11] showed that transplant center volume was not a significant predictor for post-transplant survival after correcting for disease severity and multiple donor and recipient factors in the model for end-stage liver disease (MELD) era. In the Eurotransplant region, 1632 deceased donor LT's were performed in 2015 by 39 individual centers, leading to a mean of 42 LTs per center [12]. Consequently, this broad range of low- and high-volume centers is likely to lead to a difference in experience. For pancreas transplantations in the Eurotransplant region, it was recently demonstrated that high volume is associated with a reduction in graft failure rates [13].

Besides center volume, there may be other factors influencing differences in outcome between transplant centers or a so-called center effect. Regulatory bodies in many disciplines require analysis of outcome data. In the Netherlands, the Dutch Surgical Colorectal Audit (DSCA) was initiated in 2009 to monitor, evaluate, and improve colorectal cancer care, coordinated by the Dutch Institute for Clinical Auditing (DICA) is an example of such an institute [14]. The collected data are used as a quality measure and performance indicator that make it possible for hospitals to benchmark their own results [15]. Consequences of these types of registries are improvements of quality and performance. Within the Eurotransplant region, results are currently not evaluated in this way.

The objective of this study was to investigate the effect of transplant center characteristics on outcome after LT in the Eurotransplant region in addition to the impact of donor risk (ET-DRI) [5] and recipient risk (sRRI) [6] in an attempt to provide data that can be used to comparatively evaluate the outcome of liver transplant centers, corrected for donor and recipient case-mix (quality and performance benchmarking), in a balanced, adjusted way.

Methods

Data selection

All deceased donor LT's performed in adult recipients (≥ 18 years) from January 1, 2007 till December 31, 2013 in the Eurotransplant region were included to perform a retrospective database analysis. Eurotransplant is a nonprofit organization that facilitates patient-oriented allocation and cross-border exchange of deceased donor organs and consists of eight countries (member states): Austria, Belgium, Croatia, Germany,

Hungary, Luxembourg (has no LT center), the Netherlands, and Slovenia. Liver allocation in the Eurotransplant region is discussed in detail by Jochmans *et al.* [16]. All basic donor, recipient and center characteristics (Tables 1 and 2) and follow-up data were obtained from the Eurotransplant Network Information System and the Eurotransplant Liver Registry. Follow-up data from the Eurotransplant centers are uploaded individually to the Eurotransplant database, and Eurotransplant delivers these follow-up data to the ELTR database. So, every center in Eurotransplant indirectly delivers data to the European Liver Transplant Registry (ELTR). A detailed survey on individual experience of LT surgeons was sent to each individual Eurotransplant transplant center (Table S1). The Eurotransplant Liver Intestine

Table 1. Donor and transplant characteristics ($N = 10\ 265$).

	<i>n</i> (%) / median (25th–75th percentile)
Donor factor	
Age (years)	53 (42–65)
Height (cm)	173 (165–180)
Weight (kg)	75 (68–85)
BMI	25 (23–28)
Last GGT (U/l)	38 (20–86)
Sex	
Male	5444 (53%)
Female	4821 (47%)
Cause of death	
Trauma	2178 (21%)
CVA	6286 (61%)
Anoxia	1014 (9.9%)
Other/unknown	787 (7.7%)
DCD	454 (4.4%)
Split liver	308 (3.0%)
Transplant factor	
Allocation	
Local	2565 (25%)
Regional	2558 (25%)
Extraregional	5142 (50%)
Rescue allocation	2540 (25%)
Cold ischemia time (h)	8.82 (6.98–10.72)
ET-DRI	1.89 (1.53–2.22)
Number of transplants according to center volume (according to Burroughs <i>et al.</i>)	
Low (≤ 36 transplants)	2602 (25)
Median (36–69 transplants)	5084 (50)
High (≥ 70 transplants)	2579 (25)

BMI, body mass index; GGT, gamma glutamyl-transferase; CVA, cerebral vascular accident; DCD, donation after circulatory determination of death; ET-DRI, Eurotransplant donor risk index.

Table 2. Recipient characteristics ($N = 10\,265$).

	<i>n</i> (%) / median (25th–75th percentile)
Recipient factors	
Age (years)	55 (48–61)
Height (cm)	173 (167–180)
Weight (kg)	78 (67–89)
BMI	25.7 (22.9–29.0)
Lab-MELD	18 (12–30)
Sex	
Male	6881 (67%)
Female	3384 (33%)
Primary disease on WL	
Metabolic	302 (3%)
Acute	966 (9%)
Cholestatic	1229 (12%)
Alcoholic	2335 (23%)
Malignant	2164 (21%)
HBV	327 (3%)
HCV	1042 (10%)
Other cirrhosis	1267 (12%)
Other/unknown	633 (6.2%)
Repeat transplant	1299 (13%)
Lab-MELD category	
<15	3830 (37%)
15–25	2947 (29%)
26–34	1751 (17%)
≥35	1686 (16%)
Missing values	51 (1%)
sRRI	1.96 (1.59–2.63)

BMI, body mass index; lab-MELD, laboratory model for end-stage liver disease score; WL, waiting list; HBV, hepatitis B virus; HCV, hepatitis C virus; sRRI, simplified recipient risk index.

Advisory Committee and Eurotransplant Board approved the study protocol for this study. All data were anonymized for country and transplant center.

The center-specific data were obtained by a specifically designed survey that was sent to all Eurotransplant LT centers (Table S1). Here, we specifically focused on the effect on center experience by transplant volume, which can be defined in many ways. In this study, the following four potential surrogate measures were analyzed: annual volume (the total number of transplants performed in that same year), historical volume (the mean of transplants performed in the five directly preceding years), surgical exposure (the sum of the number of transplants divided by the sum of active years of all transplant surgeons from that center both in the study period), and surgical experience (the sum of the years of experience in LT of all surgeons divided by the number of surgeons in the center). To categorize and

compare center volume, the volume limits from Burroughs *et al.* [17] were used (Table 3): low (≤ 36 transplants), median (36–69 transplants), and high (≥ 70 transplants).

Statistical analysis

Primary outcome used in the analyses was graft survival, defined as the period between the date of transplantation and date of retransplantation or date of recipient death, which ever occurred first (death-uncensored graft survival). Follow-up data until May 2016 were used in the analyses. In case of missing follow-up data, transplants were not included in the multivariate analyses. For all donors, the Eurotransplant donor risk index (ET-DRI) [5] (factors: donor age, cause of death, latest gamma glutamyl-transferase, donation after circulatory determination of death (DCD), split LT, allocation, cold ischemia time, and rescue allocation; definition described in Eurotransplant Manual [18] and by Jochmans *et al.* [16]) was calculated and for all recipients the simplified recipient risk index (sRRI) (factors: recipient age, sex, etiology of disease, laboratory MELD score, and repeated transplant). In case of missing values for donor, gamma glutamyl-transferase median values were used (28 U/l, 1.7% missing) and in case of missing cold ischemia times (43.8% missing), values were imputed five times based on a normal distribution according to the factor allocation (cold ischemia times used were as follows: local 7.41 h, regional 8.55 h, extraregional 9.80 h) in a fivefold database, in order to calculate the ET-DRI. Rubin's rules were used to pool estimates obtained from different imputed datasets. If patients received renal replacement therapy, the creatinine value was set at 4 (as of 16.12.2006, implementation of MELD for liver allocation). The MELD score was rounded to the nearest whole value (range 6–40). Two centers were excluded from the analysis due to less than 10 transplantations in the total study period, and one center was excluded based on potential data manipulation in the past [19,20].

Clinical characteristics were summarized by median and 25th–75th percentile or number and percentage for categorical factors. Comparison between groups was made using chi-square (categorical factors) or a Kruskal–Wallis test (numerical factors). Survival analyses were performed using Kaplan–Meier survival models, and multivariate analyses were performed using Cox regression models. Uncorrected/corrected funnel plots were obtained by fitting Cox proportional hazards models with fixed effects for center, unadjusted/adjusted by

Table 3. Center characteristics according to low/median/high categories ($N = 10\,265$ transplants, $n = 39$ transplant centers).

Factors	Center volume			P-value
	Low ($n = 20$ centers) $n = 2602$ transplants	Medium ($n = 15$ centers) $n = 5084$ transplants	High ($n = 4$ centers) $n = 2579$ transplants	
Donor age (year), median (25th–75th %)	52 (41–63)	52 (41–63)	56 (45–69)	<0.001
Donor BMI, median (25th–75th %)	25 (23–28)	25 (23–28)	26 (24–28)	<0.001
Donor, male sex, n (%)	1405 (54)	2694 (53)	1345 (52)	0.411
Donor DCD, n (%)	196 (7.5)	258 (5.1)	n/a	<0.001
Split liver, n (%)	58 (2.2)	185 (3.6)	65 (2.5)	0.001
Allocation, n (%)				
Local	573 (22)	1217 (24)	775 (30)	<0.001
Regional	796 (31)	1384 (27)	378 (15)	
Extraregional	1233 (47)	2483 (49)	1426 (55)	
Rescue allocation, n (%)	618 (24)	1008 (20)	914 (35)	<0.001
ET-DRI, median (25th–75th %)	1.88 (1.53–2.20)	1.86 (1.51–2.18)	1.92 (1.63–2.31)	
Recipient age (year), median (25th–75th %)	55 (48–62)	55 (47–61)	54 (48–60)	<0.001
Recipient BMI, median (25th–75th %)	26 (23–29)	26 (23–29)	26 (23–29)	0.258
Recipient lab-MELD, median (25th–75th %)	18 (11–31)	18 (11–30)	17 (12–28)	0.687
Recipient, male sex, n (%)	1791 (69)	3399 (67)	1691 (66)	0.041
Recipient primary disease, n (%)				
Acute	247 (10)	560 (11)	152 (5.9)	0.179
Cholestatic	240 (9)	660 (13)	329 (13)	
HCV	218 (8)	464 (9)	360 (14)	
sRRI	1.91 (1.59–2.63)	1.98 (1.63–2.64)	1.91 (1.59–2.60)	

BMI, body mass index; DCD, donation after circulatory determination of death; ET-DRI, Eurotransplant donor risk index; lab-MELD, laboratory model for end-stage liver disease score; HCV, hepatitis C virus; sRRI, simplified recipient risk index.

ET-DRI and sRRI (both log-transformed). Unadjusted and adjusted center effects (log hazard ratios) were then centered and plotted against the precision (1 over variance) of the centered estimates, calculated under the null hypothesis of no difference between centers. Confidence limits are plotted as $\exp(\pm 1.96/\sqrt{\text{precision}})$ for 95% confidence limits and $\exp(\pm 2.58/\sqrt{\text{precision}})$ for 99% confidence limits. The funnel plot was used to demonstrate transplant centers with graft survival rates that were significantly higher or lower than the mean within Eurotransplant (high and low outliers, transplant centers that are outside the 95% or 99% confidence limits). Two ways of correcting for possible correlation of outcomes were considered. The first was by adjusting standard errors using sandwich estimators; the second was using random-effects models. Analysis of volume–outcome relations was performed by considering the mean volume in the center over the 5 years preceding each transplantation. This “historical” volume was used to guard against reverse causation, the possibility that bad/good performance of a center leads to lower/higher volume afterward [21]. In Fig. 3, that shows the analysis of the relationship between volume

and transplantation, P-splines with four degrees of freedom were used to test for and model nonlinear relations between volume and outcome. The mean historical volume may vary every following year. For all analyses, a P -value of <0.05 was considered significant. All analyses were performed with SPSS (version 22.0) and R (version 3.3.2).

Results

The total number of included transplants was 10 265 performed in thirty-nine transplant centers (range of 21–768 LTs per center in the whole study period) during the 7-year study period (median follow-up time 3.3 years, maximum follow-up time 9.2 years). Follow-up data were missing in 387 cases (96% completeness). Demographics of donor and transplant characteristics are shown in Table 1. Median donor age was 53 years, 4.4% of all transplants were with DCD allografts, 25% with a rescue allograft, and median ET-DRI was 1.89. Twenty-five percent of all transplants were performed in a low-volume center, 50% in an intermediate volume, and 25% in a large volume center according to the “Burroughs volume

categories,” which were used as a practical example for center volume in this study [17]. A total of 30 centers (of the included 39 centers) returned a filled-out survey (75% response rate), equally divided amongst the small (80% response), medium (80% response), and large center size categories (75% response). Demographics of recipient characteristics are shown in Table 2. Median recipient age was 55 years, with a median lab-MELD at transplant of 18. The most frequently transplanted primary liver disease was alcoholic cirrhosis (23%) followed by patients with a malignant etiology of liver disease (21%). The number of repeated LT was 13%.

Center effect analyses

Demographics categorized according to low, intermediate, or large center size are shown in Table 3. Median donor age was the highest in the high-volume centers (56 vs. 52 years $P = 0.001$), and a higher percentage of extraregional (55% vs. 47% and 49%, $P < 0.001$) and rescue allocated liver allografts (35% vs. 24% and 20%, $P < 0.001$) were transplanted in high-volume centers. No DCD donors were transplanted in the high-volume centers, the percentage of DCD transplantation was the highest in low-volume centers (7.5% vs. 5.1%, $P < 0.001$). Split liver transplantation was the highest in intermediate-volume category ($P = 0.001$).

The first step was to analyze graft survival per transplant center, shown in Fig. 1a (uncorrected graft survival), in a funnel plot. Next, a funnel plot corrected for donor–recipient case-mix (donor risk measured by ET-DRI and recipient risk by sRRI) was constructed (Fig. 1b). In this figure with “risk-adjusted” graft survival rates, there were eight centers with an outcome below average (orange and red dots, hazard ratio [HR] above the 95% confidence interval), ten centers with an outcome above average (blue and green dots, HR below the 95% confidence interval), and the remaining twenty-one centers were within the 95% confidence limits (the average/majority cohort, purple dots). Differences in donor, transplant, and recipient characteristics for the centers are shown in Table 4 according to their outcome/performance. Median donor age was highest in the below-average centers (55 years vs. 52 years and 53 years, $P < 0.001$) as well as the donor BMI (26 vs. 25, $P < 0.001$). There were no DCD transplants performed in the below-average centers, whereas the highest percentage of DCD donors was used in the above-average centers (11% vs. 2%, $P < 0.001$). The below-average centers transplanted the most extraregional (62% vs. 36% and 54%, $P < 0.001$) and rescue




Figure 1 (a) Funnel plot with uncorrected graft survival rates plotted for every liver transplant center in Eurotransplant; (b) funnel plot with graft survival rates corrected for risk by donor risk Eurotransplant donor risk index (ET-DRI) and recipient risk simplified recipient risk index (sRRI), plotted for every liver transplant center in Eurotransplant: (i) orange and red dots: centers performing below average (hazard ratio above the 95% confidence interval), (ii) purple dots: centers performing within the average range, and (iii) green and blue dots: centers performing above average (hazard ratio below the 95% confidence interval).

allocated (39% vs. 22% and 19%, $P < 0.001$) allografts. The above-average centers transplanted patients with the lowest median MELD score (16 vs. 18, $P < 0.001$).

Figure 2 shows a ranking of all thirty-nine transplant centers, ranked by the HR for decreased graft survival. Figure 2a,b shows the unadjusted and (case-mix) adjusted HRs, respectively. Figure 2c shows the HR for decreased graft survival, adjusted for case-mix and random effect. This analysis shows that after using a random-effects model, there were still six centers with a significant below-average outcome than the mean and ten centers with a significant outcome above average.

Measures for center-related effects

The next step was to analyze which of the center-related factors (annual volume, historical volume, surgical experience, and surgical expertise) was associated with graft survival. The following results were found: annual volume $P < 0.001$, historical volume $P = 0.015$

Table 4. Center characteristics according to outcome in a corrected funnel plot outcome. Average outcome is defined as within the 95% confidence interval, poor above, and good below the 95% confidence interval ($N = 10\,265$ transplants, $n = 39$ transplant centers).

Factors	Outcome			P-value
	Poor performance ($n = 8$ centers, 2091 transplants)	Average performance ($n = 21$ centers, 5000 transplants)	Good performance ($n = 10$ centers, 3174 transplants)	
Donor age (year), median (25th–75th %)	55 (45–67)	52 (41–64)	53 (42–63)	<0.001
Donor BMI, median (25th–75th %)	26 (24–28)	25 (23–28)	25 (23–28)	<0.001
Donor, male sex, n (%)	1048 (50)	2679 (54%)	1717 (54%)	0.010
Donor DCD, n (%)	n/a	95 (2%)	359 (11%)	<0.001
Split liver, n (%)	36 (2%)	197 (4%)	75 (2%)	<0.001
Allocation, n (%)				
Local	348 (17%)	1210 (24%)	1007 (32%)	<0.001
Regional	458 (22%)	1085 (22%)	1015 (32%)	
Extra-regional	1258 (62%)	2705 (54%)	1152 (36%)	
Rescue allocation, n (%)	805 (39%)	1119 (22%)	616 (19%)	<0.001
ET-DRI, median (25th–75th %)	1.98 (1.69–2.32)	1.86 (1.51–2.20)	1.83 (1.51–2.14)	<0.001
Recipient age (year), median (25th–75th %)	55 (48–60)	55 (47–61)	56 (48–62)	<0.001
Recipient BMI, median (25th–75th %)	26 (23–29)	26 (23–29)	26 (23–29)	<0.001
Recipient, male sex, n (%)	1349 (65%)	3389 (68%)	2143 (68%)	0.022
Recipient lab-MELD, median (25th–75th %)	18 (11–32)	18 (12–31)	16 (10–27)	<0.001
Recipient primary disease, n (%)				
Acute	200 (10%)	509 (10%)	257 (8%)	<0.001
Cholestatic	212 (10%)	647 (13%)	370 (12%)	
HCV	220 (11%)	575 (12%)	247 (8%)	
sRRI	1.97 (1.59–2.63)	1.97 (1.59–2.64)	1.87 (1.59–2.51)	<0.001

BMI, body mass index; DCD, donation after circulatory determination of death; ET-DRI, Eurotransplant donor risk index; lab-MELD, laboratory model for end-stage liver disease score; HCV, hepatitis C virus; sRRI, simplified recipient risk index.

(nonlinearity test $P < 0.001$), surgical experience $P < 0.001$ (nonlinearity test $P < 0.001$), and surgical exposure $P = 0.029$ (nonlinearity test $P < 0.001$). For further analysis, we chose to use the historical volume as a marker for center experience, as it has a significant relation with graft survival, and historical volume is a reliable way of analyzing this factor in a longitudinal way according to the literature [21]. Figure 3 shows the results of the multivariate analysis of historical volume and the relation with the risk (HR) for decreased graft survival. The relation is nonlinear. The precise form of the curve has to be interpreted with caution, but a decreasing relative risk can be seen until the center volume reaches approximately 50 transplants (historical volume). The relative risk subsequently increases until around 100 transplants and finally decreases again.

Discussion

This study, performed with data from the Eurotransplant database covering 7 years from 2007 till 2013,

confirms that outcome (death-uncensored graft survival) differs between transplant centers in the Eurotransplant region, demonstrated with the use of funnel plots. When correcting these funnel plots of center-related risks for donor and recipient risks, with the ET-DRI and sRRI respectively, four (poor performing) centers came within the confidence intervals for graft survival. When the centers were ranked according to HR, the risk was more clearly delineated. This shows the possibility to demonstrate graft survival, corrected for donor–recipient case-mix. In light of quality control and transparency, openly sharing of outcome data is very important and requires centers to be willing to share their data. It is clear that the “best” organs in the “best” recipients risk have the best results. Hesitation or reluctance to transplant high-risk organs into high-risk recipients or to share outcome data when results seem suboptimal as compared to other centers should be overcome. Correction for case-mix is essential and will promote sharing of outcome data amongst transplant centers. In the future, it would be interesting if centers




Figure 2 (a) Ranking of all liver transplant centers in Eurotransplant according to hazard ratio (ranked from low to average to high risk, uncorrected for donor and recipient risk), with 95% confidence interval. (b) Ranking of all liver transplant centers in Eurotransplant according to hazard ratio (ranked from low to average to high risk, corrected for donor risk Eurotransplant donor risk index (ET-DRI) and recipient risk simplified recipient risk index (sRRI), with 95% confidence interval. (c) Ranking of all liver transplant centers in Eurotransplant according to hazard ratio (ranked from low to average to high risk, corrected for donor risk ET-DRI, recipient risk sRRI, and random effect, with 95% confidence interval.

could access their own individual center performance within the international allocation organization with correction for case-mix, similarly as shown in this study. This would likely improve awareness of performance based on comparisons with other centers and longitudinal developments and may thus contribute to improving quality of care and transparency for the whole transplant community.




Figure 3 Effect of center historical volume (the average number of transplants performed in the five directly preceding years) on the risk (hazard ratio) for decreased graft survival after liver transplantation (nonlinear relation).

The persisting differences between the transplant centers can be explained best by a “center effect.” This center effect can be defined as all the factors that influence outcome after LT, beyond typical factors such as donor quality and recipient risk. In view of the large variation of the practice of LT in the Eurotransplant region, these factors are influenced by local protocols, waitlist management, acceptance policy (driven by access to liver grafts or availability of liver donors, which varies amongst Eurotransplant countries [12]), legal framework (i.e., regarding the possibility of DCD LT), and potentially other unknown factors. For example, DCD LT is only performed in Belgium and the Netherlands. The differences in risk-taking behaviors between the low-/intermediate-/high-risk centers and the underperforming/medium/over performing centers, as demonstrated in, respectively, Tables 3 and 4, could have been partly caused by this variation between the Eurotransplant countries. Not only surgical experience (skills and quality), but also experience in the entire donor and transplant process, from donor management to the follow-up of recipients, may play a significant role. This experience could partly be determined by the expertise of the center or other contributors like logistical factors or factors that are not readily appreciable in the analysis of large databases (e.g., data that are not routinely collected). Therefore, it is important when evaluating center outcomes, to keep in mind that differences in case-mix and waitlist mortality between centers exist.

In an attempt to make this more visible, we divided the centers into three volume categories (low–intermediate–high). As an example, we used the proposed categories of the European Liver Transplant Registry (ELTR) study by Burroughs *et al.* in 2006 [17]. Half of all transplants were performed in intermediate-volume centers. High-volume centers transplanted liver

allografts with the highest median donor age, with highest percentage of extraregional allocated or rescue allocated allografts, as well as the highest percentage of patients listed with hepatitis C. These higher donor and recipient risks would potentially lead to inferior outcomes and were therefore corrected using the ET-DRI (donor risk), sRRI (recipient risk), and by performing a random-effects analysis. Even after these random-effects analyses centers with a significantly lower/higher risk than average remained.

To determine the best surrogate marker for center experience, we investigated four factors potentially associated with center outcome: annual volume, historical volume (mean volume over the past 5 years), surgical experience, and surgical exposure. The latter two factors were determined by a survey independent of the data analysis that was sent out to all Eurotransplant LT centers. The reason for choosing historical volume as the putatively best surrogate marker for center experience was the significant association with outcome in the analyses and based on published literature [21]. However, there are many differences in surgical practice between the Eurotransplant centers, for example, whether a LT is being performed by one or two transplant surgeons or the organization of standard operating procedures in transplantation medicine. A separate analysis, in which the specific size of the center and its association with decreased graft survival were evaluated, showed that there was no linear relation with outcome. The results showed a curve with two optimal points (low HR) with regard to graft survival; around 50 transplants per year and when performing more than 120 transplants per year (historical volume). These results differ from findings by Burroughs *et al.* [17] in another European study with ELTR data, published in 2006. Even though that study was performed with data of transplants performed between 1988 and 2003, it was a large dataset with 34 664 LTs, which showed that centers with ≥ 70 transplants per year were associated with improved patient survival at 3-month and 1-year follow-up. Based on these considerations, a limit for improved or decreased graft survival such as that a transplant center that performs 69 transplants annually would be a worse performer than a center with 70 transplants does not appear justified. In contrast, the use of a range of the number of transplants, in which a center would have less risk for decreased graft survival, would be preferable. Another difference with the ELTR study was the outcome end points employed. We looked at medium-term (3 years) graft survival as opposed to short-term patient survival, an approach

that may explain the difference in the range for the decreased risk of center volume. The improved outcomes for high-volume centers in Germany, one of the Eurotransplant countries, were recently addressed in a study by Nijboer *et al.* [22], and an editorial related to this study also suggested that there was no linear relation between outcome and center size [23], which was also seen in the present study. One explanation for this effect could be that when a center grows beyond the 50 transplants, there will first be a transition period from being an intermediate-volume to a high-volume center. Eventually, the increased exposure will lead to better results with an optimum that surpasses 120 transplants.

In 2013, Asrani *et al.* showed that the transplant center represents a significant determinant of graft failure that could provide an explanation for the disparities in outcomes after LT, with data from the Organ Procurement and Transplantation Network. Interestingly, there was no effect of center volume when donor, recipient, and transplant characteristics were taken into account. The authors suggested that the differences in outcome might well be explained by differences in surgical, medical, and/or nursing expertise that may influence the quality of care at a transplant center [7]. Unfortunately, these factors are generally not recorded in databases such as the Scientific Registry of Transplant Recipients and the Eurotransplant database. One way of looking more closely to post-transplant results on a more detailed (center) level would be with a cumulative sum (CUSUM) analysis [24,25], performed by the centers themselves. This might be a means to more rapidly implement quality improvement and performance than by means of retrospective database analyses. In light of comparing results with other centers, the risk of the center in relation to ET-DRI or sRRI might also be different.

There are several potential limitations of this study, which represents a retrospective database analysis. Eurotransplant collects many donor factors, but only basic recipient data. To correct for recipient risk, we used the sRRI that includes these basic factors as described previously. Nevertheless, additional relevant factors likely exist that may play a role in determining outcome. But because these were not recorded in the database, these could therefore not be entered into the analysis. Unfortunately, the cold ischemia times were incomplete for 44% of the transplants, which we countered by multiple imputation based on the factor allocation. Altogether, this will have only a limited impact on the ET-DRI calculation, as there is a narrow range of cold ischemia times. Another potential confounder could be the fact

that the criteria for listing on the liver transplant wait-list differ considerably per country (and even per transplant center). This is also true for the decision process of whom to transplant or not to transplant, which is dependent on the availability of donors and the allocation system employed (MELD versus non-MELD countries), as well as specific legal frameworks. All these considerations might have an impact on the center effect. Currently, the best way to correct for (part of) these factors is to use the ET-DRI and sRRI. Overall, the graph in Fig. 3 demonstrates that additional factors apart from the numerical performance of transplant centers play into the probability of graft and patient survival and that these associations have to be viewed and interpreted with caution.

Conclusions

In conclusion, our study demonstrates a center effect in liver transplantation in the Eurotransplant region by specifically looking at outcome and volume on a center-specific level. There are significant differences in graft survival rates between the Eurotransplant liver transplant centers. However, by correcting for donor and recipient risks (ET-DRI and sRRI) and random effects, these differences are partially corrected, and as such, funnel plots can be used for benchmarking purposes. The center effect consists of the whole process from preoperative workup, operation to postoperative follow-up. In this study, we also specifically analyzed center (historical) volume. Although the results have to be viewed with caution in light of the considerable differences across the countries within the Eurotransplant region, a center effect appears to be a relevant factor influencing outcome. In general, but certainly also for the centers itself, it is important to get insight in this center effect. Correcting for case-mix, using the donor-recipient model (ET-DRI + sRRI), is an elegant tool for such benchmarking efforts.

Authorship

JJB and AEB: study concept and design. JDB and HP: acquisition of data: US. Statistical analysis. JJB, JDB, HP and AEB: analysis and interpretation of data. JJB, JDB, HP and AEB: drafting of the manuscript. XR, MG, CPS, US, BH and JFH: critical revision of the manuscript.

Funding

The authors have declared no funding.

Conflicts of interest

The authors have declared no conflicts of interest.

Acknowledgements

This study was performed on behalf of the Eurotransplant Liver Intestine Advisory Committee (ELIAC). The authors thank Erwin de Vries, Eurotransplant data manager, Marieke van Meel, coordinator of the Eurotransplant Liver Registry, and the registry team for their assistance in the data retrieval. The authors acknowledge the effort of all Eurotransplant liver transplant centers that filled out and returned the survey and the all Eurotransplant liver transplant centers for providing their data.

Collaborators

Gabriela A Berlakovich⁸, Peter Michielsen⁹, Blaz Trovsek¹⁰, Branislav Kocman¹¹, László Kóbori¹², Jacques Pirenne¹³, Marieke D van Rosmalen⁷

Affiliations

⁸Department of Surgery, Medical University of Vienna, Vienna, Austria; ⁹Department of Gastroenterology and Hepatology, UZ Antwerpen, Edegem, Belgium; ¹⁰Department of Abdominal Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia; ¹¹Department of Abdominal Surgery, Division of Transplantation Surgery, University Hospital Merkur, Zagreb, Croatia; ¹²Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary; ¹³Department of Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium. All collaborators contributed to the study supervision and writing of the manuscript.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article:

Table S1. Survey on center/surgical experience.

REFERENCES

1. Feng S, Goodrich NP, Bragg-Gresham JL, *et al.* Characteristics associated with liver graft failure: the concept of a donor risk index. *Am J Transplant* 2006; **6**: 783.
2. Rana A, Hardy MA, Halazun KJ, *et al.* Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. *Am J Transplant* 2008; **8**: 2537.
3. Halldorson JB, Bakthavatsalam R, Fix OK, Reyes JD, Perkins JD. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. *Am J Transplant* 2009; **9**: 318.
4. Dutkowski P, Oberkofler CE, Slankamenac K, *et al.* Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. *Ann Surg* 2011; **254**: 745.
5. Braat AE, Blok JJ, Putter H, *et al.* The Eurotransplant donor risk index in liver transplantation: ET-DRI. *Am J Transplant* 2012; **12**: 2789.
6. Blok JJ, Putter H, Rogiers X, *et al.* The combined effect of donor and recipient risk on outcome after liver transplantation: research of the Eurotransplant database. *Liver Transpl* 2015; **21**: 1486.
7. Asrani SK, Kim WR, Edwards EB, *et al.* Impact of the center on graft failure after liver transplantation. *Liver Transplant* 2013; **19**: 957.
8. Adam R, Cailliez V, Majno P, *et al.* Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. *Lancet* 2000; **356**: 621.
9. Edwards EB, Roberts JP, McBride MA, Schulak JA, Hunsicker LG. The effect of the volume of procedures at transplantation centers on mortality after liver transplantation. *N Engl J Med* 1999; **341**: 2049.
10. Axelrod DA, Guidinger MK, McCullough KP, Leichtman AB, Punch JD, Merion RM. Association of center volume with outcome after liver and kidney transplantation. *Am J Transplant* 2004; **4**: 920.
11. Northup PG, Pruett TL, Stukenborg GJ, Berg CL. Survival after adult liver transplantation does not correlate with transplant center case volume in the MELD era. *Am J Transplant* 2006; **6**: 2455.
12. Samuel U, Branger P. Annual Report 2015. 2016; 1–164. Available from: http://eurotransplant.org/cms/mediaobject.php?file=AR_ET_20153.pdf
13. Kopp W, van Meel M, Putter H, *et al.* Center volume is associated with outcome after pancreas transplantation within the Eurotransplant region. *Transplantation* 2016; **1**: 000.
14. Van Leersum NJ, Snijders HS, Henneman D, *et al.* The Dutch surgical colorectal audit. *Eur J Surg Oncol* 2013; **39**: 1063.
15. Henneman D, Van Leersum NJ, ten Berge M, *et al.* Failure-to-rescue after colorectal cancer surgery and the association with three structural hospital factors. *Ann Surg Oncol* 2013; **20**: 3370.
16. Jochmans I, van Rosmalen M, Pirenne J. Adult liver allocation in Eurotransplant. *Transplantation* 2017; **101**: 1542.
17. Burroughs AK, Sabin CA, Rolles K, *et al.* 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. *Lancet* 2006; **367**: 225.
18. Eurotransplant Manual Chapter 5. 2013; 1–96.
19. Hyde R. German doctors call for reform after organ scandal. *Lancet* 2012; **380**: 1135.
20. Nashan B, Hugo C, Strassburg CP, Arbogast H, Rahmel AO, Lilie H. Transplantation in Germany. *Transplantation* 2017; **101**: 213.
21. French B, Farjah F, Flum DR, Heagerty PJ. A general framework for estimating volume-outcome associations from longitudinal data. *Stat Med* 2012; **31**: 366.
22. Nijboer A, Ulrich F, Bechstein WO, Schnitzbauer AA. Volume and outcome relation in German liver transplant centers: what lessons can be learned? *Transplant Res* 2014; **3**: 5.
23. Guba M. Center volume, competition, and outcome in German liver transplant centers. *Transplant Res* 2014; **3**: 6.
24. Axelrod DA, Guidinger MK, Metzger RA, Wiesner RH, Webb RL, Merion RM. Transplant center quality assessment using a continuously updatable, risk-adjusted technique (CUSUM). *Am J Transplant* 2006; **6**: 313.
25. Axelrod DA, Kalbfleisch JD, Sun RJ, *et al.* Innovations in the assessment of transplant center performance: implications for quality improvement. *Am J Transplant* 2009; **9**(4 Pt 2): 959.